Lab
Prime Laboratories LLC
Prime Laboratories LLC was paid $201K by Medicaid between Jan 2018 and Nov 2018, across 47 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 29% of everything it billed.
33Billing provider infoPRIME LABORATORIES LLC
BROKEN ARROW, OK 74012
BROKEN ARROW, OK 74012
33aNPI1508247073assigned 06/10/2015
33bProvider typeClinical Medical Laboratory
28Total paid$201K
24GClaims10,477
24DCodes billed47
24AFirst – last monthJan 2018 – Nov 2018
Compared with peers
Next to other Clinical Medical Laboratory providers in Oklahoma
Rank by total paid#25 of 46
Median peer was paid$248K
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,477 | $201K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 29% | 1,911 | 1,716 | $59K |
| 87900 | 12% | 323 | 309 | $23K | |
| 87799 | 8.6% | 306 | 292 | $17K | |
| 87500 | 3.5% | 320 | 306 | $7K | |
| 87653 | 3.5% | 320 | 306 | $7K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3.5% | 385 | 306 | $7K |
| 87641 | 3.3% | 293 | 283 | $7K | |
| 87652 | 3.3% | 321 | 307 | $7K | |
| 87640 | 3.0% | 294 | 281 | $6K | |
| 87482 | 2.8% | 277 | 267 | $6K | |
| 87481 | 2.6% | 319 | 305 | $5K | |
| 87186 | 2.1% | 130 | 124 | $4K |
35 more codes
| 83970 | 2.0% | 183 | $4K | |
| 80050 | General health panel | 1.8% | 105 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.7% | 39 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.6% | 191 | $3K |
| 87634 | 1.4% | 39 | $3K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 1.4% | 39 | $3K |
| 82172 | 1.0% | 318 | $2K | |
| 84403 | 1.0% | 189 | $2K | |
| 84481 | <1% | 198 | $2K | |
| 80061 | Lipid panel | <1% | 209 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 39 | $1K |
| 87581 | <1% | 39 | $1K | |
| 87486 | <1% | 39 | $1K | |
| 87541 | <1% | 39 | $1K | |
| 86376 | <1% | 196 | $1K | |
| 82728 | <1% | 185 | $1K | |
| 82670 | <1% | 79 | $987.66 | |
| 82607 | <1% | 107 | $929.25 | |
| 84439 | <1% | 195 | $843.67 | |
| 84144 | <1% | 79 | $805.84 | |
| 83001 | <1% | 81 | $804.37 | |
| 82533 | <1% | 139 | $779.54 | |
| 83002 | <1% | 79 | $766.19 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 193 | $739.63 |
| 84146 | <1% | 80 | $719.19 | |
| 83525 | <1% | 130 | $681.93 | |
| 83550 | <1% | 128 | $674.76 | |
| 83540 | <1% | 187 | $620.42 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,233 | $222.96 |
| 84153 | <1% | 16 | $161.12 | |
| 82627 | <1% | 15 | $153.80 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 276 | $123.87 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 65 | $71.28 |
| 80053 | Comprehensive metabolic panel | <1% | 74 | $66.09 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 75 | $41.05 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCONLEY, BEN (CEO)